Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spurious Drugs Issue: Indian Government Proposes Cash Rewards For Informers; Industry Supportive

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Grappling with increasing incidents of spurious drugs, the Indian health ministry has proposed an incentive scheme for "whistle blowers" who provide credible information and help the government in confiscating fake drugs, cosmetics or medical devices

You may also be interested in...



India’s Second Stab At Whistle Blower Policy To Curb Spurious Drug Trade

India is making renewed efforts to encourage whistle blowers to share leads and help weed out spurious drugs from the Indian market while blocking exports of such consignments.

Sanofi-Aventis India In Damage Control Mode As Local Press Errs And Says Combiflam Banned, Instead Of Comiflam

MUMBAI - The Indian arm of French multinational Sanofi Aventis went into a speedy damage control mode after several vernacular newspapers incorrectly reported that one of its biggest revenue earners Combiflam (ibuprofen/paracetamol) was banned following an order of the State Drug Authorities in Rajasthan - a state in Western India - under the provisions of the Drugs & Cosmetics Act

Sanofi-Aventis India In Damage Control Mode As Local Press Errs And Says Combiflam Banned, Instead Of Comiflam

MUMBAI - The Indian arm of French multinational Sanofi Aventis went into a speedy damage control mode after several vernacular newspapers incorrectly reported that one of its biggest revenue earners Combiflam (ibuprofen/paracetamol) was banned following an order of the State Drug Authorities in Rajasthan - a state in Western India - under the provisions of the Drugs & Cosmetics Act

Related Content

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel